


(Rac)-ErSO-DFP

Cat. No.:	HY-144070A
CAS No.:	2768139-73-5
Molecular Formula:	C ₂₀ H ₁₇ F ₅ N ₂ O ₂
Molecular Weight:	412.35
Target:	Estrogen Receptor/ERR
Pathway:	Vitamin D Related/Nuclear Receptor
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	(Rac)-ErSO-DFP is a derivative of ErSO-DFP and a selective small molecule ER α biomodulator. (Rac)-ErSO-DFP againsts ER α + breast cancer (including resistant tumors) by hyperactivating the ER α -dependent α -UPR (extracted from patent WO2022087234A1) ^[1] .								
IC₅₀ & Target	IC ₅₀ : 35 nM (MCF-7 cells) ^[1] .								
In Vitro	<p>(Rac)-ErSO-DFP (compound 2) (0.001-1 μM; 24 h) maintains potent anticancer activity with IC₅₀ of 35 nM in MCF-7 cells^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MCF-7 cells</td> </tr> <tr> <td>Concentration:</td> <td>0.001-1 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Showed a sustained activity of anticancer with IC₅₀ of 35 nM.</td> </tr> </table>	Cell Line:	MCF-7 cells	Concentration:	0.001-1 μ M	Incubation Time:	24 h	Result:	Showed a sustained activity of anticancer with IC ₅₀ of 35 nM.
Cell Line:	MCF-7 cells								
Concentration:	0.001-1 μ M								
Incubation Time:	24 h								
Result:	Showed a sustained activity of anticancer with IC ₅₀ of 35 nM.								
In Vivo	<p>(Rac)-ErSO-DFP (compound 2) (5 mg/kg; i.v.; 3xq.wk.) shows a sustained activity of againsting ERα+ breast cancer at low doses^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Ovariectomized Nu/J mice (MCF-7 orthotopic tumor model)^[1].</td> </tr> <tr> <td>Dosage:</td> <td>5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection; once-a-week for 3 total doses.</td> </tr> <tr> <td>Result:</td> <td>Maintained the ability to regress MCF-7 tumors in a mouse model of ERα+ breast cancer.</td> </tr> </table>	Animal Model:	Ovariectomized Nu/J mice (MCF-7 orthotopic tumor model) ^[1] .	Dosage:	5 mg/kg	Administration:	Intravenous injection; once-a-week for 3 total doses.	Result:	Maintained the ability to regress MCF-7 tumors in a mouse model of ER α + breast cancer.
Animal Model:	Ovariectomized Nu/J mice (MCF-7 orthotopic tumor model) ^[1] .								
Dosage:	5 mg/kg								
Administration:	Intravenous injection; once-a-week for 3 total doses.								
Result:	Maintained the ability to regress MCF-7 tumors in a mouse model of ER α + breast cancer.								

REFERENCES

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA